ABSTRACT Preeclampsia is a severe pregnancy complication in part due to insufficient implantation. This study aimed at elucidating the mechanism of action of dipeptidyl peptidase IV (DPPIV) in preeclampsia. Small activating RNAs (saRNA) were used to upregulate DPPIV expression in human trophoblast JAR cells. The DPPIV expression level was analyzed by real-time quantitative PCR and western blot and its activity was measured by luminescent protease assay. MMP-9 activity was analyzed by zymography and cell invasion by matrigel invasion assay. DPPIV expression level and activity was significantly increased by saRNA in JAR cells. DDPIV specific inhibitor diprotin A inhibited its activity at both basal and activated levels. DPPIV did not regulate MMP-9 expression but did repress MMP-9 activity. The invading ability of JAR cells was reduced by saRNA but increased by diprotin A. DPPIV might be responsible for the shallow implantation of the placenta due to its inhibition of the invading ability of extravillous trophoblasts, causing preeclampsia at later stage of pregnancy.
cells, becoming rounded with altered expression and secretion of extracellular matrix (ECM) (Menkhorst et al., 2012) .
The degradation of extracellular matrix (ECM) plays a critical role in cell migration, invading, and engraftment. Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases capable of degrading components of the ECM. MMP-9 has been shown to play roles in tissue breakdown and remodeling during aggressive tumor growth and angiogenesis (Halade et al., 2013) . The upregulation of MMP-9 associates with the increased motility of bovine trophoblast cells (Dilly et al., 2010) .
Dipeptidyl peptidase IV (DPPIV), also known as CD26, is differentially expressed in different cell population in human placenta and fetal membrane alone pregnancy. In the first trimester, DPPIV expression was mostly found in the proximal part of the cell column and undetectable in interstitial trophoblasts (Sato et al., 2002) . Diprotin A (Ile-Pro-Ile) is a specific competitive inhibitor of DDPIV that binds to the substrate-binding site of PPIV (Hiramatsu et al., 2004) and significantly enhances engraftment of human mobilized CD34+ peripheral blood cells in mice (Kawai et al., 2007) . Placental DPPIV activity was found to be significantly higher in preeclamptic placentas with intrauterine growth restriction compared to control (Nishikawa et al., 2005) , indicating that DPPIV activity might be a risk factor for preeclampsia. Increased decidual DPPIV positive lymphocytes was reported to be associated with miscarriage in human (Sehmsdorf et al., 2004) . This study aimed at elucidating the roles and relationship of DDPIV and MMPs in EVT invasion.
Results

Small RNA activates human DPPIV expression
The nucleotide sequences for the hairpin structure of three small RNAs were designed to target different regions of human DPPIV promoter (Fig. 1A) . The nucleotides were cloned into lentiviral vector PLL3.7 under the control of U6 promoter and viruses were generated in 293T cells. Two of the small RNAs activated DPPIV expression at both mRNA (Fig. 1B) and protein (Fig. 1C ) levels. The small activating RNA targeting human DPPIV promoter region starting from -134 base pair produced highest expression levels of DPPIV ( Fig. 1A and 1B) , which was chosen for later experiments and named saDPPIV.
Diprotin A inhibits saRNA induced DPPIV activity, but has no effect on DPPIV expression
To determine the effect of DPPIV inhibitor diprotin A on the expression level and activity of DPPIV in saRNA treated JAR cells, the mRNA, protein, and protease activity of DPPIV in the presence or absence of diprotin A were analyzed. In JAR cells, diprotin A did not significantly change either mRNA ( Fig. 2A) or protein (Fig. 2B ) levels of DPPIV independent of the presence of small activating RNA. However, diprotin A markedly reduced DPPIV enzymatic activity (Fig. 2C) . The DPPIV activity was significantly increased in saDPPIV cells which was repressed by diprotin A treatment (Fig. 2C ).
DPPIV inhibits MMP-2 and MMP-9 activities
The MMP-9 mRNA and protein levels in JAR cells were not significantly changed by DPPIV promoter activating small RNA compared to that of control cells or by diprotin A treatment ( Fig.  3 A ,B) . The extracellular MMP-2/9 activities analyzed by zymography showed significant change by both saDPPIV and diprotin ( Fig. 3 C,D) . The degradation of gelatin by MMP-2/9 was markedly stronger by diprotin A treated JAR cells but saDPPIV inhibited gelatin degradation.
DPPIV inhibits invasion of JAR cells
Neither lentiviruses nor working diprotin A had significant effect on the proliferation rate of JAR cells (Fig. 4A) . Diprotin A significantly increased the number of invading JAR cells in a dose dependent fashion whereas saDPPIV markedly reduced the number of invading cells compared to control (Fig. 4 B,C) . The treatment of diprotin A effectively relieved the inhibition of saDPPIV on the invasion of JAR cells (p<0.01 saDPPIV vs saDPPIV/diprotin) (Fig. 4C ).
Discussion
In human choriocarcinoma cell line JAR, DPPIV expression was significantly increased by small activating RNA targeting its proximal promoter regions, with significant increase of DPPIV mRNA, protein, and activity levels. DPPIV inhibitor diprotin A inhibited DPPIV enzymatic activity but had no impact on the expression level of DPPIV. MMP-2/9 activities and the invading ability of JAR cells were inversely correlated with DPPIV level in JAR cells. 
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RNA activation strategy has been shown to efficiently induce some tumor suppressor genes in various cancers in vitro and in vivo (Kang et al., 2012) , which inhibited cancer cell proliferation and tumor growth. The saRNA-induced E-cadherin overexpression resulted in the suppression of migration and invasion of human bladder cancer cells in vitro (Kang et al., 2012) . DPPIV expression level was elevated in JAR cells by lentivirus-delivered saRNA targeting DPPIV gene promoter regions.
Systemic DPPIV inhibition with sitagliptin enhanced engraftment during umbilical cord blood (UCB) transplantation in adult with hematological malignancies (Farag et al., 2013) , which might be due to the reverse of DPPIV-caused downregulation of CXCL12-induced chemotactic response (Christopherson et al., 2006) . On the other hand, DPPIV was found to mediate granulocyte colonystimulating factor mobilization of hematopoietic stem and progenitor cells (Broxmeyer et al., 2007) . Moreover, DPPIV and other adhesion molecules on syncytiotrophoblast microvillous membranes were able to inhibit the proliferation of cultured human umbilical vein endothelial cells (HUVEC) (Kertesz et al., 2000) which was suspected through competition for ligands in ECM or serum with receptors on HUVEC. It seemed that DPPIV might have different roles other than chemotaxis in placenta. Current data demonstrated that DPPIV might inhibit trophoblast invasion during placenta implantation by inhibiting the activities of specific MMPs. The N-terminus of human MMP-9 proprotein starts with APRQRQST and MMP-2 with APSPIIKF. Xaa-Pro is the preferred substrate of DDPIV (Scharpé et al., 2001) , indicating that the activities of MMP-2 and MMP-9 might be regulated through a process initiated by N-terminus truncation by DDPIV.
It has been shown that DPPIV suppresses the growth and progression of many cancer cells (Wesley et al., 2004) but also found overexpressed in type II diabetes, chronic liver diseases, and various malignant tumors (Itou et al., 2013) , indicating its function varies among different tissues and cells. DPPIV mediates G-CSF mobilization, engraftment, and survival of hematopoietic stem and progenitor cells (Broxmeyer et al., 2007) but suppresses NSCLC cells (Wesley et al., 2004) . By using saRNA and DPPIV inhibitor diprotin A, an inverse relationship between DPPIV activity and the invading ability of human choriocarcinoma JAR cells was established. This line of data is consistent with in vivo findings that DPPIV was highly expressed in the EVTs of the proximal part of the cell column or into deep section of the decidua and myometrium but turned off in the migrating EVTs (Sato et al., 2002) . Furthermore, DPPIV might inhibit extravillous trophoblast invasion through repressing the activity of certain ECM degrading enzyme such as MMP-2 and MMP-9. 
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In conclusion, human DPPIV expression was activated by small activating RNA that targets specific region in DPPIV promoter. Increased expression level and activity of DPPIV repressed the activities of MMP-2 and MMP-9 and decreased JAR cell invading ability, indicating that dysregulation of DPPIV expression might be responsible for abnormal implantation of placenta and causes preeclampsia at later stage of pregnancy.
Materials and Methods
Cell culture
Human choriocarcinoma cell line JAR was obtained from the American Type Culture Collection (Manassas, VA). The cells were maintained in Dulbecco's modified Eagle's medium/Ham's nutrient mixture F12 (Invitrogen, Shanghai, China) supplemented with 10% FBS (Hyclone, Beijing, China), 100 IU/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Shanghai, Chian) at 37°C in a humidified atmosphere (5% CO 2 ). Diprotin A was added at a specified final concentration where indicated.
Design and verification of saRNA
Three small activating RNA candidates were designed targeting different regions of human DDPIV gene promoter. The nucleotide sequences of the synthesized polynucleotides were: Sa77: TGC-CATTCAAGAGGGAACAATCTTCAAGAGAGATTGTTCCCTCTT-GAATGGCTTTTTTC and tcgaGAAAAAAGCCATTCAAGAGGGAA-CAATCTCTCTTGAAGATTGTTCCCTCTTGAATGGCA; sa134: TGCAAGACAATCGGGAAATTCCTTCAAGAGAGGAATTTCCC-GATTGTCTTGCTTTTTTC and tcgaGAAAAAAGCAAGACAATC-GGGAAATTCCTCTCTTGAAGGAATTTCCCGATTGTCTTGCA; sa515: TGCACATTGTAACCACTCAAACTTCAAGAGAGTTTGAGTGGTTA-CAATGTGCTTTTTTC and tcgaGAAAAAAGCACATTGTAACCACT-CAAACTCTCTTGAAGTTTGAGTGGTTACAATGTGCA. Each pair were annealed and cloned into XhoI/HpaI digested pLL3.7 lentiviral vector and confirmed by DNA sequencing (Invitrogen, Shanghai, China). Three saRNA and saControl viruses were packaged in 293T cells in the presence of three packaging vectors. The lentiviral vector cloning and lentivirus production were completed by Chi Biotechnology (Jiangyin, China). The viral titer was assayed by serial dilution and infection of 293T cells followed by fluorescence-activated cell sorting (FACS) analysis. Four viruses individually infected JAR cells and RNA was analyzed by RT-qPCR 3 days later.
Quantitative real-time PCR
JAR cells infected with control or saDPPIV lentivirus at 5 multiplicity of infection when they reached about 90% confluence. Twenty-four hr postinfection, the cells were treated with 10 mmole/L of diprotin A or vehicle for 24 hr before collected for RNA or protein work. Total RNA was extracted from cells using Trizol reagent (Invitrogen, Shanghai, China) according to manufacturer's instruction. RNA concentration and purity were analyzed by UV spectrophotometer. 1mg of total RNA was reverse transcribed into cDNA according to kit instructions (Transgen, Beijing, China). After 1:3 dilution of cDNA with ddH 2 O, 2 ml of diluted cDNA was used as template for real-time PCR using 2×TransStart Green qPCR supermix (Transgen, China). Primers used were designed with Primer3 online software. AGTG-GCGTGTTCAAGTGTGG and CAAGGTTGTCTTCTGGAGTTGG for DP-PIV; ACGACGTCTTCCAGTACCGA and CTGGTTCAACTCACTCCGGG for MMP9; TCCATGACAACTTTGGTATCG and TGTAGCCAAATTCGTT-GTCA for GAPDH (internal control). Fluorescence quantitative PCR was performed on an ABI 7300 (Life Technologies, Carlsbad, CA). The relative expression level was calculated by 2 <<t method.
Western blot
The protein was resolved by SDS-polyacrylamide gel electrophoresis before transferred onto a PVDF membrane. The membrane was blocked with 5% non-fat milk and immunoblotted with anti-DPPIV antibody (ab28340, Abcam, Cambridge, MA), followed by secondary antibody incubation. An enhanced chemiluminescence (ECL) (Sangon, Shanghai, China) method was used to detect the protein bands.
DPPIV activity assay
DDPIV protease activity in cells treated with saDPPIV in the presence or absence of diprotin A was measured by DPPIV-Glo™ Protease Assay kit from Promega (Madison, Wisconsin) according to manufacturer's manual.
MTT
JAR cells were digested with 0.25% trypsin into single cell suspension and seeded into 96-well plates at 2000 cells per well. The next day, the cells were infected with 5 MOI of control or saDPPIV lentivirus followed by 24 hr later being treated with 10 mmole/L of diprotin A for another 24 h. Then 20 mL of 0.5% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each well and incubated for 4 h at 37ºC. The medium was carefully removed and 150 mL of dimethyl sulfoxide (DMSO) was added to each well. The absorbance was measured at 492 nm on a microplate reader after 30 min incubation in dark at room temperature with shaking. The OD value of untreated cells was set as 1. The experiment was performed 3 times independently in 6 replicates.
Cell invasion assay
Two days after saDPPIV or saControl lentivirus infections, 5×10 4 cells in serum-free media in the presence or absence of 5 or 20 mmole/L diprotin A were seeded into the upper chambers of a 24-well Matrigel invasion chamber (BD, Shanghai, China). Medium with 10% FBS was added to the lower chambers. Invading cells were fixed and stained with H&E 12 hr later. The cell number from five high power fields of each treatment was counted.
Gelatin zymography measure MMP-2/9 activities
Protein was resolved on a 7.5% acrylamide gel co-polymerized with gelatin (BDH Chemical Co, Poole, UK) at a final concentration of 1 mg/ ml with a 4.5% acrylamide stacking gel. Gels were run in standard Trisglycine-SDS running buffer A SeeBlue molecular weight ladder (Invitrogen, Shanghai, China) was used for size determination. Gels were washed in water and wash buffer (50 mmol/L Tris-HCl pH 8.0, 5 mmol/L CaCl 2 and 2.5% (v/v) Triton X-100) twice each with agitation at room temperature (30 minutes for each wash). The gels were then rinsed three times in water before incubating in 50 ml of 1% (vol/vol) Triton X-100 in 20 mmol/L Tris-HCl, pH 7.8 and 5 mmol/L CaCl 2 at 37°C for 20 hours. The gel was scanned and analyzed with ImageJ software.
Statistical analysis
All experiments were performed three times. Data were expressed as mean ± standard error or representative images were shown. The difference between treatment was analyzed by one-way ANOVA using Graphpad Prism 6. It was considered statistically significant if p value was less than 0.05.
